Share on LinkedInShare on LinkedIn

ARTICLE · 17 JUNE 2022

Protecting Pharmaceutical Trademarks In Saudi Arabia

Khurana & Khurana, Advocates and IP Attorneys
Explore more from Khurana & Khurana, Advocates and IP Attorneys

The creation and distribution of counterfeit pharmaceutical products and active pharmaceutical components has serious ramifications for consumer health and safety, and is compounded...

Saudi ArabiaIntellectual Property

Protecting pharmaceutical trademarks in Saudi Arabia

According to reports, the Arab pharmaceutical business is worth over $20 billion and is expected to increase at a compound annual growth rate of about 9% between 2012 and 2016. In the region, there are about 450 pharmaceutical companies. All Middle Eastern countries, with the exception of Egypt, are large importers of branded medications, while domestic production capabilities are primarily limited to generic and licenced drugs with little R&D. As a result, it is becoming increasingly vital for trademark holders to face the issues of pharmaceutical trademark protection in the Arab world and to get more familiar with the regional standards.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from